Perspective Therapeutics (NYSE:CATX) Now Covered by Wedbush

Wedbush initiated coverage on shares of Perspective Therapeutics (NYSE:CATX) in a research note issued to investors on Tuesday, Marketbeat reports. The firm issued an outperform rating and a $25.00 price target on the stock. Wedbush also issued estimates for Perspective Therapeutics’ Q3 2024 earnings at ($0.22) EPS, Q4 2024 earnings at ($0.29) EPS, FY2024 earnings at ($0.92) EPS, Q1 2025 earnings at ($0.36) EPS, Q2 2025 earnings at ($0.43) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($1.80) EPS, FY2026 earnings at ($1.95) EPS, FY2027 earnings at ($2.03) EPS and FY2028 earnings at ($1.54) EPS.

Other equities analysts have also issued research reports about the stock. Truist Financial assumed coverage on shares of Perspective Therapeutics in a report on Wednesday, September 25th. They set a buy rating and a $21.00 target price on the stock. Bank of America assumed coverage on shares of Perspective Therapeutics in a research report on Thursday, July 25th. They set a buy rating and a $24.00 price target for the company. Cantor Fitzgerald reiterated an overweight rating on shares of Perspective Therapeutics in a report on Monday, September 9th. Royal Bank of Canada dropped their target price on Perspective Therapeutics from $29.00 to $27.00 and set an outperform rating for the company in a report on Friday, August 16th. Finally, Oppenheimer reduced their price target on Perspective Therapeutics from $19.00 to $17.00 and set an outperform rating on the stock in a research report on Tuesday, August 13th. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of Buy and an average target price of $20.71.

Perspective Therapeutics Price Performance

Shares of CATX stock opened at $13.42 on Tuesday. The business’s 50-day moving average price is $13.80. Perspective Therapeutics has a 12-month low of $2.20 and a 12-month high of $19.05.

Perspective Therapeutics (NYSE:CATX) last released its earnings results on Monday, August 12th. The company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.04. The firm had revenue of $0.53 million during the quarter. Equities research analysts anticipate that Perspective Therapeutics will post -0.86 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Perspective Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Sykon Capital LLC raised its holdings in shares of Perspective Therapeutics by 4.7% during the second quarter. Sykon Capital LLC now owns 37,932 shares of the company’s stock valued at $378,000 after acquiring an additional 1,717 shares in the last quarter. Victory Capital Management Inc. purchased a new position in Perspective Therapeutics during the 2nd quarter valued at $117,000. Point72 DIFC Ltd bought a new position in Perspective Therapeutics in the 2nd quarter worth $118,000. SG Americas Securities LLC purchased a new stake in shares of Perspective Therapeutics in the 3rd quarter worth about $246,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Perspective Therapeutics during the 2nd quarter valued at about $188,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.